TY - JOUR
T1 - International validation of the low anterior resection syndrome score
AU - Juul, Therese
AU - Ahlberg, Madelene
AU - Biondo, Sebastiano
AU - Emmertsen, Katrine Jøssing
AU - Espin, Eloy
AU - Jimenez, Luis Miguel
AU - Matzel, Klaus E.
AU - Palmer, Gabriella
AU - Sauermann, Anna
AU - Trenti, Loris
AU - Zhang, Wei
AU - Laurberg, Søren
AU - Christensen, Peter
N1 - (C) 2014 by Lippincott Williams & Wilkins
PY - 2014/4
Y1 - 2014/4
N2 - OBJECTIVE:: The aims of this study were to investigate the convergent and discriminative validity and reliability of the low anterior resection syndrome (LARS) score in an international setting. BACKGROUND:: The LARS score is a simple self-administered questionnaire measuring bowel dysfunction after rectal cancer surgery. The score is intended to be commonly used in international research and clinical practice in the future. Therefore, a thorough validation in an international setting is of utmost importance. METHODS:: The LARS score was translated using methods in keeping with current international recommendations. A total of 801 patients operated for rectal cancer in Sweden, Spain, Germany, and Denmark completed the LARS score questionnaire, including an anchor question assessing the impact of bowel function on quality of life. A subgroup of 218 patients completed the LARS score twice. Data were analyzed per country. RESULTS:: The LARS score has demonstrated a high convergent validity in terms of a high correlation between LARS score and quality of life (P < 0.001). Sensitivity ranged from 67.7% to 88.3% and specificity from 58.1% to 86.3%. The LARS score was able to discriminate between groups of patients differing with regard to radiotherapy, surgery, and age (P < 0.05). The score also demonstrated high reliability at test-retest with narrow limits of agreement and no statistically significant difference between scores at the first and second test. CONCLUSIONS:: The Swedish, Spanish, German, and Danish versions of the LARS score have proven to be valid and reliable tools for measuring LARS in European rectal cancer patients.
AB - OBJECTIVE:: The aims of this study were to investigate the convergent and discriminative validity and reliability of the low anterior resection syndrome (LARS) score in an international setting. BACKGROUND:: The LARS score is a simple self-administered questionnaire measuring bowel dysfunction after rectal cancer surgery. The score is intended to be commonly used in international research and clinical practice in the future. Therefore, a thorough validation in an international setting is of utmost importance. METHODS:: The LARS score was translated using methods in keeping with current international recommendations. A total of 801 patients operated for rectal cancer in Sweden, Spain, Germany, and Denmark completed the LARS score questionnaire, including an anchor question assessing the impact of bowel function on quality of life. A subgroup of 218 patients completed the LARS score twice. Data were analyzed per country. RESULTS:: The LARS score has demonstrated a high convergent validity in terms of a high correlation between LARS score and quality of life (P < 0.001). Sensitivity ranged from 67.7% to 88.3% and specificity from 58.1% to 86.3%. The LARS score was able to discriminate between groups of patients differing with regard to radiotherapy, surgery, and age (P < 0.05). The score also demonstrated high reliability at test-retest with narrow limits of agreement and no statistically significant difference between scores at the first and second test. CONCLUSIONS:: The Swedish, Spanish, German, and Danish versions of the LARS score have proven to be valid and reliable tools for measuring LARS in European rectal cancer patients.
KW - Bowel dysfunction
KW - functional outcome
KW - low anterior resection syndrome score
KW - rectal neoplasms
KW - validation
UR - http://www.scopus.com/inward/record.url?scp=84895929987&partnerID=8YFLogxK
U2 - 10.1097/SLA.0b013e31828fac0b
DO - 10.1097/SLA.0b013e31828fac0b
M3 - Article
C2 - 23598379
AN - SCOPUS:84895929987
VL - 259
SP - 728
EP - 734
IS - 4
ER -